Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain

BACKGROUND: Icatibant is the only subcutaneous treatment for acute Type I and Type II hereditary angioedema with C1-esterase inhibitor deficiency (HAE-C1-INH) licensed for self-administration in Europe. AIM: To compare the economic impact of two icatibant administration strategies: health profession...

Descripción completa

Detalles Bibliográficos
Autores principales: Blasco, Antonio J, Lázaro, Pablo, Caballero, Teresa, Guilarte, Mar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584739/
https://www.ncbi.nlm.nih.gov/pubmed/23398817
http://dx.doi.org/10.1186/2191-1991-3-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584739/
https://www.ncbi.nlm.nih.gov/pubmed/23398817
http://dx.doi.org/10.1186/2191-1991-3-2

Ejemplares similares